Clinical Trials Logo

Clinical Trial Summary

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39P, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma


Clinical Trial Description

his is an open-label, dose-escalation/dose extension study to assess the safety, tolerability, and efficacy of LUCAR-G39P in the patient ≥ 18 years of age with relapsed or refractory B-cell non-Hodgkin lymphoma. Subjects who meet the eligibility criteria will receive a single dose of LUCAR-G39P injection. The study will include the following sequential phases: screening, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06295549
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact Huayuan Zhu, PhD,MD
Phone +86-13813810650
Email huayuan.zhu@hotmail.com
Status Recruiting
Phase Phase 1
Start date April 11, 2024
Completion date June 30, 2028